Specializing in targeted therapeutic trials
Oncology clinical trials are usually longer and more complex than those targeting other diseases. In addition to the medical and scientific issues, enrollment can be a challenge: although cancer is the second-leading cause of death in the United States, fewer than 3% of cancer patients currently enroll in clinical trials for new treatments. And with the progress of the Human Genome Project in recent years, there is an entirely new generation of cancer drugs that offer therapies targeted to the genomics of an individual patient and an individual cancer.
This growing string of drug candidates has accentuated drug developers’ need for rapid and accurate clinical trial results.
An oncology CRO & drug development resource
Medelis’ team includes world-class oncology drug development talent who understand the future of personalized medicine and threshold of credibility trials. Our extensive worldwide contacts and involvement with the research community keep us close to research trends and developments. Simply put, we know when new agents are coming into clinical development, and we work with our clients to create the best strategy to move treatments through the clinic. And while in the clinic, you’ll receive the comfort knowing that our management team, project managers and CRAs all have deep oncology experience to complement their skills in operational and technical matters.
This portfolio of expertise means faster, more accurate results and more strategic long-term drug development planning.
Learn more about our experience managing oncology clinical trials.